Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 3, 2026, 11:57 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 601–624 of 7,594 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Bones Clear all

Conditions: Osteoporosis
Interventions: ALX1-11 50 mcg, placebo, ALX1-11 75mcg, ALX1-11; Drug
Lead sponsor: Shire; Industry
Eligibility: 50 Years to 75 Years · Female only
Enrollment: 217 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1995 – 1997
U.S. locations: 15
States / cities: Peoria, Arizona • Loma Linda, California • Mill Valley, California + 12 more

Conditions: Myelodysplastic Syndromes
Interventions: Decitabine/Cedazuridine, Magrolimab; Drug
Lead sponsor: Astex Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023
U.S. locations: 3
States / cities: New Haven, Connecticut • Plantation, Florida • Minneapolis, Minnesota

Conditions: Hurler Syndrome
Interventions: Laronidase; Drug
Lead sponsor: Masonic Cancer Center, University of Minnesota; Other
Eligibility: Up to 14 Years
Enrollment: 11 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2016
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Osteosarcoma, Leukemia, Lymphoma
Interventions: glucarpidase, high-dose methotrexate, leucovorin, high-dose methotrexate, leucovorin; Drug
Lead sponsor: BTG International Inc.; Other
Eligibility: Not listed
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 25
States / cities: Phoenix, Arizona • Los Angeles, California • Oakland, California + 20 more

Conditions: Childhood-onset Growth Hormone Deficiency, Pituitary Dwarfism
Interventions: recombinant human growth hormone; Biological
Lead sponsor: EMD Serono; Industry
Eligibility: 13 Years to 25 Years
Enrollment: 31 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 9
States / cities: Orange, California • Jacksonville, Florida • Orlando, Florida + 6 more

Conditions: Hypercalcemia of Malignancy, Lung Cancer, Metastatic Cancer, Pain, Unspecified Adult Solid Tumor, Protocol Specific
Interventions: zoledronic acid, quality-of-life assessment; Drug · Procedure
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 1998 – 2001
U.S. locations: 55
States / cities: Birmingham, Alabama • Springdale, Arkansas • Gilroy, California + 48 more

Conditions: Myeloproliferative Disorder, Myeloproliferative Syndrome, Myelofibrosis, Polycythemia Vera, Essential Thrombocythemia
Interventions: USDA Diet, Mediterranean Diet; Other
Lead sponsor: University of California, Irvine; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Irvine, California

Conditions: Acute Myeloid Leukemia, Myelodysplastic Syndromes, Myeloproliferative Neoplasms, Chronic Myelomonocytic Leukemia, Myelofibrosis
Interventions: Ipilimumab, CD25hi Treg depleted DLI; Drug · Biological
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Psoriatic Arthritis
Interventions: Open label H.P. Acthar Gel; Drug
Lead sponsor: Fiechtner, Justus J., M.D., P.C.; Individual
Eligibility: 18 Years to 75 Years
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2014
U.S. locations: 1
States / cities: Lansing, Michigan

Conditions: Degenerative Disc Disease, Degenerative Spondylolisthesis, Spinal Degeneration, Spinal Stenosis
Interventions: Computed Tomography (CT) Scan of the Lumbar Spine; Radiation
Lead sponsor: Bone and Joint Clinic of Baton Rouge; Other
Eligibility: 18 Years and older
Enrollment: 66 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2020
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Cytopenia, MDS
Interventions: PERIBLOOD-MDS; Diagnostic Test
Lead sponsor: Weizmann Institute of Science; Other
Eligibility: 18 Years and older
Enrollment: 1,500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: San Diego, California • Miami, Florida

Conditions: Metastatic Renal Cell Carcinoma
Interventions: Pazopanib, Sorafenib, Radium-223; Drug
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2019
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Osteoporosis
Interventions: ALX1-11 (drug); Drug
Lead sponsor: Shire; Industry
Eligibility: 45 Years and older · Female only
Enrollment: 1,683 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2001 – 2005
U.S. locations: 84
States / cities: Birmingham, Alabama • Huntsville, Alabama • Phoenix, Arizona + 75 more

Conditions: Kidney Transplantation
Interventions: TCD601; Biological
Lead sponsor: ITB-Med LLC; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 4 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 1
States / cities: New York, New York

Conditions: Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), de Novo Myelodysplastic Syndromes, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia
Interventions: decitabine, fludarabine phosphate, busulfan, cyclophosphamide, tacrolimus, mycophenolate mofetil, filgrastim, total-body irradiation, allogeneic bone marrow transplantation, laboratory biomarker analysis; Drug · Biological · Radiation + 2 more
Lead sponsor: University of Wisconsin, Madison; Other
Eligibility: 18 Years to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 1
States / cities: Madison, Wisconsin

Conditions: Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Blasts 5 Percent or More of Bone Marrow Nucleated Cells, Myelodysplastic/Myeloproliferative Neoplasm, Philadelphia Chromosome Positive, Recurrent Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Secondary Acute Myeloid Leukemia, T Acute Lymphoblastic Leukemia
Interventions: Cytarabine, Laboratory Biomarker Analysis, Recombinant EphB4-HSA Fusion Protein, Vincristine Liposomal; Drug · Other · Biological
Lead sponsor: University of Southern California; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2020
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
Interventions: hydroxyurea, laromustine; Drug
Lead sponsor: Vion Pharmaceuticals; Industry
Eligibility: 18 Years and older
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 3
States / cities: Baltimore, Maryland • Durham, North Carolina • Houston, Texas

Conditions: Acute Graft vs Host Disease, Allogeneic Bone Marrow Transplantation, Adverse Effects
Interventions: Prednisone; Drug
Lead sponsor: John Levine; Other
Eligibility: Up to 21 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2026
U.S. locations: 10
States / cities: Los Angeles, California • Washington D.C., District of Columbia • Atlanta, Georgia + 6 more

Conditions: HIV, Osteoporosis
Interventions: Not listed
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 19 Years to 99 Years
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2012 – 2014
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndrome
Interventions: Non-myeloablative allogeneic stem cell transplant with prophylactic activated DLI, "Prophylactic" delayed ADLI, "Prophylactic" delayed activated donor lymphocyte infusion; Drug
Lead sponsor: Abramson Cancer Center at Penn Medicine; Other
Eligibility: 18 Years to 70 Years
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2009
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Fractures
Interventions: Laser beam guidance; Procedure
Lead sponsor: Loma Linda University; Other
Eligibility: 18 Years to 89 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009 – 2011
U.S. locations: 1
States / cities: Loma Linda, California

Conditions: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Acute Myeloid Leukemia, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Acute Myeloid Leukemia, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive
Interventions: Decitabine, Ponatinib, Venetoclax; Drug
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Myelodysplastic Syndromes
Interventions: Metoclopramide; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: 18 Years to 72 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2008
U.S. locations: 2
States / cities: Bethesda, Maryland • Seattle, Washington

Conditions: Acromegaly
Interventions: Pegvisomant, Sandostatin LAR; Drug
Lead sponsor: Pfizer; Industry
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2006
U.S. locations: 13
States / cities: Los Angeles, California • Chicago, Illinois • Boston, Massachusetts + 8 more

Search by objective public record fields.

A Study to Assess the Safety and Efficacy of 3 Doses of ALX1-11 (50, 75, and 100µg) in the Treatment of Postmenopausal Osteoporosis

A Study of Oral Decitabine/Cedazuridine in Combination With Magrolimab in Participants With Intermediate- to Very High-Risk Myelodysplastic Syndromes (MDS)

Administration of IV Laronidase Post Bone Marrow Transplant in Hurler

Open-label Leucovorin Pharmacokinetic Study in Patients Receiving High Dose Methotrexate With or Without Voraxaze

Cool.Click™ Adolescent Transition Study: Study of Saizen® in Subjects With Childhood-onset Growth Hormone Deficiency

Zoledronate in Treating Patients With Solid Tumors That Have Spread to the Bone

The NUTRIENT Trial (NUTRitional Intervention Among myEloproliferative Neoplasms): Feasibility Phase

A Phase 1 Trial of CD25/Treg-depleted DLI Plus Ipilimumab for Myeloid Disease Relapse After Matched-HCT

Protocol for H.P. Acthar Gel in Moderately to Severely Active Psoriatic Arthritis

Fibergraft Interbody Fusion Retrospective

Replacing Bone Marrow Diagnostics With Peripheral Blood Analysis in Cytopenia Patients

Exploratory Study of Radium-223 and VEGF-Targeted Therapy in Patients With Metastatic Renal Cell Carcinoma and Bone Mets

Open Label Extension Study of PREOS

A Study of TCD601 in the Induction of Tolerance in Renal Transplantation (PANORAMA)

Decitabine and Total-Body Irradiation Followed By Donor Bone Marrow Transplant and Cyclophosphamide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia

EphB4-HSA Fusion Protein and Cytarabine /or Liposomal Vincristine in Patients With Recurrent or Refractory Acute Leukemia

VNP40101M in Treating Patients With Acute Myelogenous Leukemia or High-Risk Myelodysplasia

Pediatric GVHD Low Risk Steroid Taper Trial

Fracture and Bone Mineral Density in HIV+ Patients Recently Started on Antiretroviral Therapy (ART)

Enhancing Graft vs Leukemia Via Delayed Ex-Vivo Co-Stimulated DLI After Non-Myeloablative Stem Cell Transplantation

Radiation Exposure Using Laser Guided Fluoroscopy in Various Orthopaedic Procedures

Decitabine, Venetoclax, and Ponatinib for the Treatment of Philadelphia Chromosome-Positive Acute Myeloid Leukemia or Myeloid Blast Phase or Accelerated Phase Chronic Myelogenous Leukemia

Metoclopramide to Treat Anemia in Patients With Myelodysplastic Syndrome (MDS)

A Study To Compare The Efficacy And Safety Of Pegvisomant To That Of Sandostatin Lar Depot In Patients With Acromegaly